26 December 2017 | News
Dr.Reddy's Laboratories has launched Melphalan Hydrochloride for Injection
A therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection is launched by Dr. Reddy’s laboratories in the United States market.
The drug, which is used to treat certain types of cancer, was earlier approved by the US Food and Drug Administration (USFDA).
According company, IMS Health figures shows the Alkeran brand and generic drug had US sales of approximately $107 million for the most recent twelve months ending in October 2017.
Dr. Reddy's Melphalan Hydrochloride for Injection is available in a carton.
The carton consisting of one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.